Compare Abeona Therapeutics Inc (ABEO) vs Sea Limited (SE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Sea Limited — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Sea Limited trades at $105 (market cap $63.84B). The key difference: Sea Limited is far larger — about 171× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals.
| ABEO | SE | |
|---|---|---|
Market Cap | $373.32M | $63.84B |
Sector | Health | Media |
52-Week High | $7.23 | $196.50 |
52-Week Low | $4.17 | $78.16 |
Enterprise Value | $228.22M | $56.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Sea Limited (SE) trades at $104.23, up 0.9% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong revenue growth, with 2025 revenue reaching $22.94 billion and net income of $1.58 billion, though recent quarters have mixed earnings performance. Analyst consensus remains strongly positive with a $131 price target, supported by improving cash flow trends and expanding profitability.
The outlook for SE is favorable given robust growth in its digital ecosystem and positive analyst sentiment, but risks include competitive pressures in Southeast Asian markets and potential volatility from earnings misses. Investors should weigh the high P/E ratio of 41.34 against the company's accelerating top-line expansion and margin improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
